PL428992A1 - Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą - Google Patents

Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą

Info

Publication number
PL428992A1
PL428992A1 PL428992A PL42899219A PL428992A1 PL 428992 A1 PL428992 A1 PL 428992A1 PL 428992 A PL428992 A PL 428992A PL 42899219 A PL42899219 A PL 42899219A PL 428992 A1 PL428992 A1 PL 428992A1
Authority
PL
Poland
Prior art keywords
degree
determining
gal
patient
protein
Prior art date
Application number
PL428992A
Other languages
English (en)
Other versions
PL240124B1 (pl
Inventor
Ewa Łucja Stępień
Agnieszka Kamińska
Original Assignee
Uniwersytet Jagielloński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński filed Critical Uniwersytet Jagielloński
Priority to PL428992A priority Critical patent/PL240124B1/pl
Priority to PCT/PL2020/050020 priority patent/WO2020171724A1/en
Publication of PL428992A1 publication Critical patent/PL428992A1/pl
Publication of PL240124B1 publication Critical patent/PL240124B1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6827—Total protein determination, e.g. albumin in urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules

Abstract

Przedmiotem zgłoszenia jest sposób określanie stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą, charakteryzuje się tym, że w próbce moczu od pacjenta cierpiącego na cukrzycę określa się stężenie białka gal-3, przy czym: wartość stężenia białka gal-3 w moczu poniżej 11,06 ng/mL świadczy o istnieniu u tego pacjenta stopnia uszkodzenia nerek odpowiadającego umiarkowanie ciężkiemu lub ciężkiemu obniżeniu współczynnika przesączania kłębuszkowego eGFR poniżej 44 ml/min/1,73 cm2, wartość stężenia białka gal-3 w moczu powyżej 11,06 ng/mL świadczy o istnieniu u tego pacjenta stopnia uszkodzenia nerek odpowiadającego umiarkowanemu, niewielkiemu lub łagodnemu obniżeniu współczynnika przesączania kłębuszkowego eGFR do wartości powyżej 44 ml/min/1,73 cm2.
PL428992A 2019-02-21 2019-02-21 Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą PL240124B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL428992A PL240124B1 (pl) 2019-02-21 2019-02-21 Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą
PCT/PL2020/050020 WO2020171724A1 (en) 2019-02-21 2020-02-21 Method of determination of the degree of renal damage occurring in subjects with diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL428992A PL240124B1 (pl) 2019-02-21 2019-02-21 Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą

Publications (2)

Publication Number Publication Date
PL428992A1 true PL428992A1 (pl) 2020-08-24
PL240124B1 PL240124B1 (pl) 2022-02-21

Family

ID=70334017

Family Applications (1)

Application Number Title Priority Date Filing Date
PL428992A PL240124B1 (pl) 2019-02-21 2019-02-21 Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą

Country Status (2)

Country Link
PL (1) PL240124B1 (pl)
WO (1) WO2020171724A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND THEIR USES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6106277B2 (ja) * 2012-10-05 2017-03-29 日立化成株式会社 尿中エキソソームｍＲＮＡおよびそれを用いて糖尿病性腎症を検出する方法

Also Published As

Publication number Publication date
PL240124B1 (pl) 2022-02-21
WO2020171724A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
WO2012040073A3 (en) Biomarkers of renal injury
MX2019007500A (es) Antagonistas de il-6 para aumentar la albumina y/o disminuir la crp.
Calvi et al. When is it appropriate to order an ionized calcium?
MX2018013099A (es) Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5- il)-piridin-3-il)metoxi)benzaldehido.
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
EP3773880A4 (en) Therapeutic modulation to treat blood glucose abnormalities, including type 2 diabetes, and/or reduce hba1c levels, and associated systems and methods
WO2007143098A8 (en) Hepatocyte growth factor (hgf) binding proteins
DK2719708T3 (da) Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme
ATE462427T1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
TW200621722A (en) 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
WO2009021754A3 (en) Monospecific and multispecific antibodies and method of use
DK1446157T3 (da) Antistoffer til inhibering af blodkoagulation og fremgangsmåder til anvendelse deraf
BRPI0413119A (pt) uso de anticorpos com adcc otimizada para tratar pacientes debilitados
WO2004097429A3 (en) Apociii and the treatmentand diagnosis of diabetes
PL428992A1 (pl) Sposób określania stopnia uszkodzenia nerek pojawiającego się u chorych z cukrzycą
WO2015095097A3 (en) Inhibitors of the renal outer medullary potassium channel
NZ703225A (en) Superior efficacy of cd37 antibodies in cll blood samples
EA200870232A1 (ru) Kcnq-открыватели калиевых каналов, применяемые для лечения или ослабления симптомов шизофрении
EA202190302A1 (ru) Соединения 2,6-диаминопиридина
EA201991676A1 (ru) Ингибиторы nhe-опосредованного антипорта
WO2015028469A3 (en) Marker for statin treatment stratification in heart failure
PL1841316T3 (pl) Białko CCN3 do zastosowania w leczeniu i diagnozowaniu chorób nerek
WO2006010533A3 (en) Pancreatic polypeptide as target/marker of beta cell failure
MX2020002206A (es) Factor de crecimiento de fibroblastos 21 (fgf-21) modificado para usarse en metodos para tratar la esteatohepatitis no alcoholica (nash).
MX2022007875A (es) Nuevos marcadores proteicos de da?o renal.